Physician profile
Timothy Lubenow
NPI 1922024470
$556,152.54
in general payments reported to CMS, 2019-2025
34 companies · $27K in 2025
The $27K reported for 2025 was more than what 97% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $139K · 2020: $102K · 2021: $72K · 2022: $74K · 2023: $105K · 2024: $37K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $96K · Food and Beverage: $26K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $22K · Travel and Lodging: $19K · Consulting Fee: $5,600 · Education: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,148.75 |
| Food and Beverage | $25,686.88 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $21,980.00 |
| Travel and Lodging | $18,727.79 |
| Consulting Fee | $5,600.00 |
| Education | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $245,739.05 | 2019-2025 | Proclaim, Eterna, Prodigy |
| Boston Scientific Corporation | $160,106.29 | 2019-2025 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16, Click |
| Nevro Corp. | $69,297.65 | 2019-2024 | Senza |
| Vertiflex, INC. | $26,978.29 | 2019 | |
| Biotronik Nro, INC. | $14,974.82 | 2023-2025 | Prospera, Biotronik |
| Abbvie INC. | $7,722.27 | 2021-2024 | |
| Painteq LLC | $7,333.96 | 2021-2025 | Painteq |
| Medtronic, INC. | $6,485.70 | 2021-2025 | Synchromedii, Intellis Adaptivestim |
| Flowonix Medical Incorporated | $5,505.97 | 2019 | |
| Medtronic USA, INC. | $4,423.76 | 2020 | |
| Spinal Simplicity, LLC | $2,990.96 | 2022-2025 | Ha Minuteman G3-R |
| Spr Therapeutics, INC | $758.95 | 2019-2023 | Sprint Pns System |
| Relievant Medsystems, INC. | $758.14 | 2020-2023 | Intracept |
| Saluda Medical Americas, INC. | $555.07 | 2022-2025 | Evoke Scs, Evoke |
| Mml US, INC. | $443.89 | 2024 | Reactiv8 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $349.33 | 2023-2024 | Mild Device Kit |
| Nalu Medical, INC. | $254.40 | 2022-2024 | Nalu Neurostimulation System |
| Curonix LLC | $220.07 | 2022-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Tersera Therapeutics LLC | $201.16 | 2019-2024 | Prialt |
| Globus Medical, INC. | $196.51 | 2025 | Vyrsa V1 |
| Allergan, INC. | $125.98 | 2021 | |
| Stimwave Technologies Incorporated | $116.99 | 2022 | |
| Collegium Pharmaceutical, INC. | $113.93 | 2021-2025 | Belbuca, Xtampza |
| Pfizer INC. | $100.08 | 2023-2024 | |
| Grt US Holding, INC. | $95.42 | 2022 | |
| Biotronik INC. | $73.79 | 2025 | Prospera |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.31 | 2019-2025 | Relistor |
| Si-Bone, INC. | $36.33 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $32.27 | 2021 | |
| Redhill Biopharma INC. | $27.85 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.39 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.54 | 2021 | |
| Almatica Pharma LLC | $15.78 | 2023 | Gralise |
| Astrazeneca Pharmaceuticals Lp | $13.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Lubenow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.